<DOC>
	<DOCNO>NCT00248079</DOCNO>
	<brief_summary>To evaluate clinical safety , efficacy , pharmacokinetics ( PK ) Endeavor Resolute Zotorolimus Eluting Coronary Stent System treatment single de novo lesion native coronary artery reference vessel diameter ( RVD ) 2.5 3.5 mm diameter .</brief_summary>
	<brief_title>The Medtronic RESOLUTE Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1 . Patient least 18 year old 2 . Patient acceptable candidate percutaneous coronary intervention emergent coronary artery bypass graft surgery 3 . Patient clinical evidence ischemic heart disease positive functional study 4 . Female patient childbearing potential must negative pregnancy test within 7 day trial procedure 5 . Patient patient 's legal representative inform nature trial agrees provision provide write informed consent approve Human Research Ethics Committee respective investigational site 6 . Patient agree comply specify followup evaluation return investigational site procedure perform . Patients participate PK substudy must agree additional followup procedure require substudy 1 . Known hypersensitivity contraindication aspirin , heparin bivalirudin , clopidogrel ticlopidine , cobalt , nickel , chromium , molybdenum , polymer coating component sensitivity contrast medium , adequately premedicated 2 . History allergic reaction significant sensitivity drug ABT578 , rapamycin , tacrolimus , everolimus , analogue derivative 3 . Platelet count &lt; 100,000 cells/mm³ &gt; 700,000 cells/mm³ , white blood cell ( WBC ) count &lt; 3,000 cells/mm³ 4 . Serum creatinine level &gt; 170 micromol/L within 7 day prior index procedure 5 . Evidence acute myocardial infarction within 72 hour intend trial procedure ( define : Q wave myocardial infarction nonQ wave myocardial infarction CK enzymes &gt; 2X laboratory upper limit normal presence elevate CKMB ( amount laboratory upper limit normal ) ) 6 . Previous stenting anywhere target vessel 7 . PCI target vessel within 30 day prior procedure 8 . Implantation drug elute stent nontarget vessel within 30 day prior procedure . Implantation Cypher stent nontarget vessel within 90 day prior procedure 9 . PCI nontarget vessel bare metal stent within 30 day prior procedure result MACE event . If bare metal stent implant within 72 hour prior procedure , post procedural serial CK CKMB measurement investigational site 's upper limit normal ( two upper normal required enrollment ) 10 . PCI nontarget vessel within 24 hour prior procedure 11 . Planned PCI vessel within 30 day postprocedure . Planned stenting vessel Cypher Endeavor stent within 60 day postprocedure 12 . Planned PCI target vessel within 9 month postprocedure 13 . During index procedure , target lesion require treatment device PTCA prior stent placement 14 . History stroke transient ischemic attack within prior 6 month 15 . Active peptic ulcer upper gastrointestinal bleeding within prior 6 month 16 . History bleed diathesis coagulopathy refuse blood transfusion 17 . Concurrent medical condition life expectancy le 12 month 18 . Any previous plan treatment target vessel antirestenotic therapy include , limited brachytherapy 19 . Currently participate investigational drug another device trial complete primary endpoint clinically interfere current trial endpoint ; require coronary angiography , IVUS coronary artery imaging procedure 20 . Documented leave ventricular ejection fraction &lt; 30 % recent evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Coronary Disease</keyword>
</DOC>